MANA Therapeutics

MANA Therapeutics’ EDIFY™ Platform Represents the Next Generation of Cell Therapy by Harnessing Natural Immune System Pathways to Train T Cells to Target Unique Antigen Sets Expressed by Tumors, Without Genetic Modification. We Are Using EDIFY to Develop Off-the-Shelf Allogeneic T-Cell Therapies to Deliver Safe and Effective Responses Across Multiple Cancers.MANA Currently Has Two Programs Advancing Through Our Internal Pipeline:1. MANA-312 is an Allogeneic Donor-Derived Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) in the Relapsed/Refractory Post-Transplant Setting, Which Has Received FDA Clearance to Initiate Our First Clinical Study.2. MANA-412 is Our Next-Generation Off-the-Shelf Allogeneic Cell Therapy Currently in Preclinical Studies for AML Patients Unsuitable for Transplant and Solid Tumors.MANA Is Also Engaging in Discussions With Multiple Partners With Proprietary Antigens to Enable the Development of Collaborative MANA Products for a Broad Range of Cancer Indications (MANA-512).